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Increased vascular reactivity associated with cyclosporin A (CsA)-induced arterial hypertension might result
from increased vasoconstriction and/or decreased vasodilatation. The administration of organic NO donors could
have beneficial effects by the NO-cGMP reposition, but there is the risk of sympathetic nervous system worsening
by neuro-hormonal counter-regulation. We evaluate the effect of preventive and regressive (curative) isosorbide 5-
mononitrate (Is-5-Mn) treatment on blood pressures and on plasma, platelets, adrenals, left ventricle and aorta
norepinephrine (NE) and epinephrine (E) contents, assessed by HPLC, in CsA-induced hypertensive rats. Five rat
groups were tested: control (orange juice), CsA (5 mg/kg/day) and Is-5-Mn (150 mg/kg/day, bid) groups were
treated for 7 weeks; preventive group (Is-5-Mn+CsA): Is-5-Mn during 2 weeks plus 7 weeks of Is-5-Mn+CsA;
regressive group (CsA+Is-5-Mn): CsA during 7 weeks plus 5 weeks of CsA+Is-5-Mn. The increased BP in the
CsA group was prevented, but was not reverted, by concomitant Is-5-Mn treatment. In the CsA-treated rats, there
was a noticeable decrease in left ventricle NE and E contents and aorta NE levels and a moderate increase in
circulating catecholamines, without significant effect in the adrenals values. When Is-5-Mn was preventively used,
the CsA-induced effect on left ventricle and aorta was prevented. Concomitantly, however, the plasma–platelet
catecholamine balance was disrupted, accumulating NE in plasma, whereas E increased in aorta, mimic the single
Is-5-Mn-treated group. In opposition, in the group used as regressive Is-5-Mn therapy, the adrenals contents were
higher compared with the CsA-group and, simultaneously, the CsA-evoked effects on circulating, left ventricle and0024-3205/$ -
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F. Reis et al. / Life Sciences 77 (2005) 2514–2528 2515aorta catecholamines were not reverted. In conclusion, regressive Is-5-Mn therapy was unable to attenuate CsA-
induced catecholamine changes and BP values even worsened. On the contrary, preventive Is-5-Mn treatment
prevented the catecholamine changes on left ventricle and aorta, but increased plasma NE and aorta E
accumulation. Even though with those effects, hypertension development was totally prevented, suggesting that
peripheral SNS per se cannot fully explain CsA-induced hypertension. Furthermore, Is-5-Mn might produce
beneficial effects only if preventively employed but, considering the changes on peripheral catecholamine
contents, a judicious evaluation of the nitrate therapy impact is recommended in order to avoid further deleterious
effects.
D 2005 Elsevier Inc. All rights reserved.
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Introduction
Cyclosporin A (CsA) has greatly improved morbidity and mortality in transplanted patients during the
last decades (Cortesini, 2004). However, albeit the high immunosuppressive efficacy, its clinical use is
commonly associated with undesirable serious side effects, such as nephrotoxicity (Cattaneo et al., 2004)
and arterial hypertension development (Textor et al., 2000). The prevalence rate for this posttransplant
hypertension is elevated (between 65 and 100%, according to Taler et al., 1999) and might endanger the
transplant successful and long-term allograft survival (Mange et al., 2000).
Although widely investigated, the pathophysiological mechanisms underlying CsA-induced
hypertension are not fully elucidated until now; but an increased vascular reactivity seems to be a
consensual data (Cartier et al., 1994). The activation of sympathetic neural pathways leading to
adrenergically mediated vasoconstriction has been proposed. Almost all the animal studies have been
suggesting a CsA-induced sympathetic overactivation, by means of increased pre-synaptic neurotrans-
mitter release, augmented vascular contraction in response to nerve stimulation, altered catecholamine
contents or enhanced neurotransmission (Xue et al., 1987; Duruibe et al., 1990; Lyson et al., 1994;
Zhang and Victor, 2000). Our previous studies, through the evaluation of peripheral catecholamine
contents in rats under CsA treatment with therapeutic-related doses, have also suggested a relevant
sympathetic dysfunction (Reis et al., 2000; Tavares et al., 2003). However, in human transplant
recipients, the results were miscellaneous. While some studies have suggested an increased neural traffic
related with CsA administration (Scherrer et al., 1990; Seals et al., 1993; Sander et al., 1996; Lucini et
al., 2000; van de Borne et al., 2001), others have indicated normal or decreased sympathetic activity or
no determinant influence for the CsA-hypertension (Floras et al., 1991; Elam et al., 1993; Kaye et al.,
1993; Stein et al., 1995; Carvalho et al., 1999; Bouhaddi et al., 2004). The time elapsed after
transplantation might possibly explain some of the discrepant results (van de Borne et al., 2001).
However, the use of adrenergic modulators as primary treatment for CsA-induced hypertension remains
debatable.
Decreased vasodilatation, as well as increased vasoconstriction, might play a central role in the
exacerbated vascular reactivity. Actually, CsA-associated endothelial damage and decreased endothe-
lium-dependent and independent relaxation were also previously demonstrated (Zoja et al., 1986;
Stephan et al., 1995; El-Mas et al., 2004). Nitric oxide (NO) participates in the blood pressure control
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pathway impairment has been gaining substantial attention during the last years (Marumo et al., 1995;
Oriji and Keiser, 1998). However, despite widely studied, its contribution for the CsA-induced vascular
dysfunction and hypertension, as well as the possible benefits of l-arginine supplementation (the most
tested therapeutic intervention), remains incompletely elucidated (O’Neil et al., 1991; Stroes et al., 1997;
Lassila et al., 2001; Santiago et al., 2003; El-Mas et al., 2004). In previous studies from our group, while
l-arginine administration has shown inefficacy in preventing CsA-induced hypertension (Reis et al.,
2002), the preliminary results with a different NO donor drug, the organic nitrate isosorbide 5-
mononitrate (Is-5-Mn), have demonstrated promising results (Reis et al., 2003).
Despite those beneficial effects, long-term nitrate dietary supplementation might interfere with the
sympathetic activity, namely as a result of compensatory counter-regulation (Megson, 2000). Thus, this
work intended to study the effect of preventive and regressive (curative) Is-5-Mn treatment on blood
pressures and on plasma, platelets, adrenals, left ventricle and aorta norepinephrine (NE) and
epinephrine (E) contents in CsA-induced hypertensive rats.Material and methods
Animals and diets
Male Wistar rats (Charles River Laboratories Inc., Barcelona, Spain), 280–300 g, were maintained
in an air conditioned room (22–24 8C) with humidity of 60%, subjected to 12-h dark–light cycles and
given standard laboratory rat chow (IPM-R20, Letica, Barcelona, Spain) and water ad libitum. Animal
experiments were conducted according to the European Convention on Animal Care, and the
Portuguese Foundation for Science and Technology approved the research project containing the
study. After a period of adaptation of at least 1 week, the rats were divided into 5 groups (each with
8 rats) treated with the following oral diets: control group-receiving only orange juice during 7
weeks; CsA group-receiving 5 mg/kg body weight (BW)/day of CsA (Sandimmune NeoralR,
Novartis Farma), dissolved in orange juice, for the period of 7 weeks; Is-5-Mn group-receiving 150
mg/kg BW/day (bid) of Is-5-Mn (MonoprontR, Ferraz-Lynce SA) during 7 weeks; preventive group
(Is-5-Mn+CsA)-receiving 150 mg/kg BW/day (bid) of Is-5-Mn for 2 weeks and the same dose of Is-
5-Mn plus CsA (5 mg/kg BW/day) during an additional period of 7 weeks; regressive group
(CsA+Is-5-Mn)-receiving 5 mg/kg BW/day of CsA during 7 weeks and the same dose of CsA plus
150 mg/kg BW/day (bid) of Is-5-Mn for the additional period of 5 weeks. All the administrations
were performed using an appropriate esophagi canola, between 1700 h and 1800 h for control and
CsA-treated rats. In order to have a daily nitrate-low/free period of about 4–5 h to overcome
hypothetic organic nitrate tolerance, Is-5-Mn bid administration was made asymmetrically at 1000
h and at 1700 h. All the determinations were carried out in all the rat groups at the end of the
corresponding treatments: week 7 for the control, CsA and Is-5-Mn groups, week 9 for the Is-5-
Mn+CsA group and week 12 for CsA+Is-5-Mn group. The CsA dose of 5 mg/kg/day was chosen
because the rat blood concentrations achieved are well-correlated with the human bmaintenanceQ dose
used in clinical practice of transplantation (Tavares et al., 2002). Is-5-Mn dose was selected by means
of preliminary studies concerning its efficacy in preventing CsA-induced hypertension development
(Reis et al., 2003).
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Systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean blood pressure (MBP) and
heart rate (HR) values were obtained using a tail-cuff sphygmomanometer LE 5001 (Letica, Barcelona,
Spain) in appropriate contention cages. Before the measurements, the rats were warmed for 10–20 min at
25–30 8C in order to allow the detection of tail artery pulsations and to achieve the pulse level ready. BP and
HRvalues were obtained by averaging 8–10measurements. Tominimize stress-induced fluctuations in BP,
all the rats were adapted to appropriate cages and to measurements during at least 2 weeks before the
beginning of administrations. The same person took the final values in the same peaceful environment
between 1400 h and 1800 h. Blood pressure and HR were assessed in all the rat groups under study, at
several different periods of treatment: a group of 30 rats was random chosen between the rats of all the
groups before the beginning of treatments, in order to be used as the time 0 value; the control and the CsA
group were assessed at the end of the treatments (week 7); the Is-5-Mn+CsA group was evaluated before
the concomitant CsA administration (Is-5-Mn group-week 2) and at the end of the treatment (week 9); the
CsA+Is-5-Mn group was measured before simultaneous Is-5-Mn administration (CsA group-week 7) and
at the end of the treatment (week 12).
Body and tissues (cardiac and adrenal) weights and hypertrophy indexes
At the end of each treatment, the body weight (BW), the whole heart weight (HW), the left ventricle
weight (LVW) and the adrenals (2: left plus right) weight (AW) were measured in all the rats under
study. The cardiac hypertrophy indexes were indicated by the heart weight in grams per kilogram body
weight (HW/BW) and by the left ventricle weight in grams per kilogram body weight (LVW/BW). The
adrenals hypertrophy index was expressed by the adrenals weight (2: left and right) in grams per
kilogram body weight (AW/BW).
Catecholamine assay
NE and E levels in plasma, platelets, adrenals, left ventricular tissue and aorta tissue were evaluated
by HPLC, using 3,4-dihydroxybenzylamine (DHBA) as internal standard.
Plasma and platelet sample preparation
The platelet pellet and the plasma samples from all the rat groups were obtained as previous described
(Reis et al., 2000) and added reduced glutathione (0.250 M) to prevent amine degradation. In brief, 2 ml
of each of these fractions, 100 ng/ml of DHBA, 50 mg of alumina and 1 ml of Tris–HCl buffer (1.5 M,
pH 8.6) containing 0.1 M Na2-EDTA were added. The mixture was then shaken for 10 min, allowed to
stand for a few minutes to sediment alumina, and the supernatant was aspirated. The alumina was then
washed three times with ultra-pure water and transferred to an appropriate microfilter system, where
adsorbed catecholamines were finally obtained by centrifugation (1000g for 1 min) after having added
perchloric acid (0.1 M).
Aorta, adrenals and left ventricle sample preparation
At the end of each treatment, the rats were sacrificed by cervical dislocation and the aorta, the adrenal
glands and the heart were immediately removed, placed in ice-cold Krebs’ buffer, carefully cleaned of
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tissue and a small segment of the abdominal aorta were then homogenized in perchloric acid (0.1 M,
Sigma) at 4 8C and then centrifuged at 2500g for 15 min at 4 8C. The supernatant was filtered by
microcentrifuge filter (Spin-X HPLC, CostarR, Corning Inc. NY, USA) and the filtrate was used for the
catecholamine assay, performed according to above described conditions.
Chromatographic conditions
The HPLC system consisted of a Gilson Applied Chromatographic System with a Biophase ODS
RP18 analytical column (2504.6, F=5 A; Bioanalytical Systems Inc., U.S.A.). Separation and
detection was achieved using the conditions previously described (Reis et al., 2000) in an isocratic
solvent system of acetate–citrate buffer (sodium acetate 0.1 M, citric acid 0.1 M), containing sodium 1-
octanesulfonate (0.5 mM), EDTA (0.15 mM), dibutylamin (1 mM) and 10% methanol.
Catecholamine levels quantification
NE and E contents were measured by using known concentrations of the corresponding standards
(Sigma Chemical Co.) and the internal standard DHBA, and were quantified by means of the peak area
ratio. Chromatograms were obtained using the appropriate software (Gilson 712 HPLC Controller
version 1.30, Gilson Medical Electronics Inc., Villiers-Le-Bel, France). Concentrations were expressed
in: ng/ml for plasma, pg/109plat. for the platelets, Ag/g wet tissue for the adrenals and ng/g wet tissue for
left ventricle and aorta.
Drugs
Cyclosporin A (Sandimmune NeoralR) was given by Novartis Pharma, Lisbon, Portugal; isosorbide
5-mononitrate (MonoprontR) was supplied by Ferraz, Lynce SA (Lisbon, Portugal). Alumina was
purchased from Bioanalytical Systems Inc. (West Lafayette, ID, U.S.A.). The solvents of high purity for
the chromatographic quantifications were obtained from Merk (Darsmstadt, Germany). The internal
standard DHBA and the catecholamine standards, as well as all the other chemicals were purchased from
Sigma Chemical Co. (St. Louis, MO, U.S.A).
Statistical analysis
Results were expressed as meansF standard error of the mean (SEM). Groups were tested for
differences by performing ANOVA followed by Fisher’s Protected-Least-Significant-Difference (PLSD)
post-hoc test, using the Statview 4.53 software from Abacus Concepts Inc. (Berkeley, CA, USA).
Differences were considered statistically significant at a value Pb0.05 (*Pb0.05; **Pb0.01 and
***Pb0.01: vs. the control group; yPb0.05; yyPb0.01 and yyyPb0.001 vs. the CsA-treated group).Results
Blood pressures and heart rate
After 7 weeks of CsA treatment, there was a significant SBP, DBP and MBP increase (Pb0.001 for
each) when compared with the control (Table 1). In opposition, in the Is-5-Mn+CsA rats, no significant
Table 1
Systolic, diastolic and mean blood pressure and heart rate in the control, CsA, Is-5-Mn+CsA, CsA+Is-5-Mn and Is-5-Mn
groups throughout the treatments
Group n SBP (mm Hg) DBP (mm Hg) MBP (mm Hg) HR (beats/minutes)
Before treatments 30
Random group 111.6F0.7 94.6F1.0 100.1F0.7 341.3F3.0
After treatments 8
Control 114.9F3.1 99.1F1.8 104.3F1.9 339.1F6.3
CsA 146.2F4.5*** 124.9F4.5*** 136.6F5.8*** 375.5F6.9**
Is-5-Mn+CsA 114.3F1.9zzz 97.0F3.3zzz 100.4F4.0zzz 368.4F11.9
CsA+Is-5-Mn 159.7F5.5z 132.8F2.8 140.2F3.0 389.2F10.8
Is-5-Mn 116.8F2.4 104.1F2.6 108.5F2.6 360.0F6.8*
CsA: cyclosporin A; Is-5-Mn: isosorbide 5-mononitrate; SBP: systolic blood pressure; DBP: diastolic blood pressure; MBP:
mean blood pressure; HR: heart rate. Values are meansFS.E.M. of n (indicated) rats. Significant differences between the
groups are expressed: **P b0.01 and ***P b0.001 vs. the control group; zP b0.05 and zzzP b0.001 vs. the CsA group.
F. Reis et al. / Life Sciences 77 (2005) 2514–2528 2519differences were obtained when compared with the control (after 2 weeks of single Is-5-Mn treatment or
at the end of Is-5-Mn+CsA administration). However, statistically significant lower values were
demonstrated when compared with the CsA group (Table 1). That is, the CsA-induced BP rise was
prevented. Contrarily, in the group firstly treated only with CsA during 7 weeks and then with both drugs
for an additional period of 5 weeks (CsA+Is-5-Mn group), the systolic (Pb0.05), the diastolic and the
mean BP have revealed even higher values than those of the CsA group, demonstrating no CsA-induced
hypertension reversion. Quite the opposite, even a worsening of the effect was observed (Table 1).
Heart rate values were also significantly higher in the CsA-treated rats (Pb0.01) when compared with
those of the control group. The single Is-5-Mn group also has demonstrated a higher HR value (Pb0.05)
in comparison with the control group. In the preventive and regressive Is-5-Mn groups (Is-5-Mn+CsA
and CsA+ Is-5-Mn, respectively), the CsA-induced HR increment was not prevented or reverted, being
the values identical to those of the CsA group (Table 1).
Cardiac and adrenal glands weights and hypertrophy indexes
The body, whole heart, left ventricle and adrenals weights were evaluated at the end of treatments:
week 7 for the control, CsA and Is-5-Mn groups; week 9 for the Is-5-Mn+CsA group and week 12 for
the CsA+Is-5-Mn group. The cardiac weights (HW and LVW) and hypertrophy indexes (HW/BW and
LVW/BW) were identical in all the groups under study (Table 2). Concurrently, no statistically
significant differences were encountered in adrenals weight (2: left plus right) and hypertrophy index
(AW/BW) between the 5 groups (Table 2).
Plasma and platelet catecholamine levels
After 7 weeks of treatment in the CsA-treated rats, the plasma NE (1.66F0.15 ng/ml) and E
(0.49F0.04 ng/ml) levels were numerically higher than those of the control rats (NE: 1.33F0.20 ng/ml;
E: 0.37F0.04 ng/ml), but without reaching statistically significance. Similar values were also obtained
in the Is-5-Mn group (Fig. 1A1 and A2). The groups treated concomitantly with CsA and Is-5-Mn
demonstrated different patterns. Actually, in the preventive group (Is-5-Mn+CsA), there were
Table 2
Weights of the body, whole heart, left ventricle and adrenals and cardiac and adrenal hypertrophy indexes in the control, CsA,
Is-5-Mn+CsA, CsA+Is-5-Mn and Is-5-Mn groups at the end of the corresponding treatments
Group BW (kg) HW (g) LVW (g) HW/BW (g/kg) LVW/BW (g/kg) AW (g) AW/BW (g/kg)
Control 0.38F0.01 1.17F0.05 0.88F0.05 3.11F0.11 2.34F0.11 0.092F0.013 0.24F0.30
CsA 0.42F0.01 1.23F0.09 0.93F0.06 2.93F0.23 2.29F0.21 0.090F0.006 0.21F0.16
Is-5-Mn+CsA 0.38F0.01 1.21F0.03 0.86F0.03 3.18F0.08 2.29F0.08 0.094F0.005 0.24F0.12
CsA+Is-5-Mn 0.42F0.01 1.21F0.06 0.94F0.08 2.85F0.07 2.21F0.18 0.078F0.006 0.18F0.15
Is-5-Mn 0.39F0.03 1.11F0.04 0.85F0.03 2.87F0.12 2.21F0.21 0.085F0.029 0.22F0.07
CsA: cyclosporin A; Is-5-Mn: isosorbide 5-mononitrate; BW: body weight; HW: whole heart weight; LVW: left ventricle
weight; AW: adrenals (2) weight; HW/BW (g/kg): heart weight in grams per kilogram body weight; LVW/BW (g/kg): left
ventricle weight in grams per kilogram body weight; AW/BW (g/kg): adrenals weight (2: left and right) in grams per kilogram
body weight. Values are meansFS.E.M. of 8 rats for each group.
F. Reis et al. / Life Sciences 77 (2005) 2514–25282520significantly increased NE levels (2.28F0.45 ng/ml; Pb0.05) and tendentious (not significant) higher E
contents, indicating an effect even more pronounced than the effect observed in the CsA group. In
opposition, in the group used as regressive therapy (CsA+Is-5-Mn), no significant differences in NE and
E contents were obtained when compared with the CsA-treated rats (Fig. 1A1 and A2).0
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Fig. 1. Plasma (A) and platelet (B) norepinephrine (1) and epinephrine (2) concentrations in the control, CsA, Is-5-Mn+CsA,
CsA+Is-5-Mn and Is-5-Mn groups. Values are meansFS.E.M. of 8 rats for each group. Significant differences between the
groups are expressed: *P b0.05; **P b0.01; ***P b0.001; NS: Non-significant.
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Pb0.05) in the CsA group than in the control, without significant differences on E levels (Fig. 1B1 and
B2). In the Is-5-Mn treated rats, there were significant lower values of NE and E in comparison with the
control. Moreover, similar concentrations were also found in the Is-5-Mn+CsA group, being the values
of NE and E statistically significant (Pb0.01 and Pb0.05) when compared with those of the CsA group.
These data indicate that when the rats were previously treated with Is-5-Mn before the concomitant
administration with CsA, the effect of the single Is-5-Mn treatment was maintained. On the other hand,
in the CsA+Is-5-Mn group, the results were identical to those obtained in the single CsA-treated group,
being platelet NE level even higher than in the CsA group and E concentration also unchanged (Fig. 1B1
and B2). While the preventive Is-5-Mn treatment seems to essentially preserve the effects observed in the
group treated solely with Is-5-Mn, the regressive Is-5-Mn treatment seems to only slightly affect the CsA
effects already established, demonstrating no regressive corrections.
Peripheral tissues (adrenals, left ventricle and aorta) catecholamines levels
The NE and E contents in the adrenals of the CsA-treated rats were identical to those of the control
group. In the group first treated with Is-5-Mn during 2 weeks and further simultaneously administrated0
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5-Mn groups. Values are meansFS.E.M. of 8 rats for each group. Significant differences between the groups are expressed:
*P b0.05; **P b0.01; NS: Non-significant.
F. Reis et al. / Life Sciences 77 (2005) 2514–25282522with CsA for 7 weeks (Is-5-Mn+CsA), the concentrations were also similar to those observed in the
CsA and in the control rats (Fig. 2). However, both in the group treated singly with Is-5-Mn and in the
group treated initially with CsA and then with CsA and Is-5-Mn (CsA+Is-5-Mn), there were
significantly higher NE and E contents (Pb0.05 for both catecholamines) when compared with the CsA
group (Fig. 2).
The left ventricular tissue NE content was lower (Pb0.05) in the CsA-treated group than in the
control (Fig. 3A1). Concurrently, E concentration was highly inferior in the CsA group than in the
control (Pb0.001) (Fig. 3A2). In the Is-5-Mn group, the NE and E levels were identical to those of the
control group, which seems to indicate no particular effect of Is-5-Mn on the left ventricular mechanisms
of NE and E accumulation and release. The groups treated concomitantly with CsA and Is-5-Mn
demonstrated different patterns. Therefore, in the group preventively tested (Is-5-Mn+CsA), the CsA-
induced left ventricular NE (Pb0.05) and E (Pb0.001) changes were totally prevented, being the
numerical values identical to those of the control group. On the contrary, in the group used as regressive
therapy (CsA+Is-5-Mn), no significant differences in NE and E contents were obtained when compared
with the CsA-treated rats (Fig. 3A1 and A2), which suggests the inexistence of regressive effect of Is-5-
Mn when the CsA-induced changes were already present.0
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Fig. 3. Left ventricle (A) and aorta (B) norepinephrine (1) and epinephrine (2) contents in the control, CsA, Is-5-Mn+CsA,
CsA+Is-5-Mn and Is-5-Mn groups. Values are meansFS.E.M. of 8 rats for each group. Significant differences between the
groups are expressed: *P b0.05; **P b0.01; ***P b0.001; NS: Non-significant.
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E concentration found was identical in both groups (Fig. 3B1 and B2). The preventive Is-5-Mn treatment
has prevented the CsA-induced NE content decrease (Pb0.001) and, simultaneously, has increased the
E accumulation. The value obtained was highly significant (Pb0.001) when compared with the CsA
group, in which a normal aorta E accumulation was demonstrated. The Is-5-Mn+CsA group effect
resembles the pattern observed in the group treated solely with Is-5-Mn, where normal NE and higher E
concentration in aorta was found (Fig. 3B1 and B2). In the CsA+Is-5-Mn group, identical NE and E
aorta contents were obtained compared to those of the CsA-treated rats, demonstrating no ability to
revert the CsA-induced effects.Discussion
In this study, the therapeutic application of Is-5-Mn to prevent/attenuate CsA-evoked BP rise
originated divergent effects: when used preventively (Is-5-Mn+CsA group), the hypertension was
prevented and when employed as regressive/curative therapy (CsA+Is-5-Mn group), the BP rise was
even higher. This discovery opens good perspectives for the organic nitrates, in particular for Is-5-Mn, as
therapy for CsA-induced arterial hypertension development if preventively used. Furthermore, the effect
was demonstrated even after a large period (7 weeks) of concomitant treatment with CsA, indicating that
if administered bi-daily in asymmetrical doses before the CsA treatment, as was done in our study, it
does not originate relevant tolerance and lost of effect given that the preventive effect on BP rise was
maintained. When the CsA effects were already established, the same lack of tolerance by concomitant
Is-5-Mn treatment could not be ensured since it was inefficient in attenuating/reverting hypertension
development.
Previous studies from our group, using this rat model treated with CsA doses related with those used
in clinical therapeutic practice to prevent allograft rejection, have suggested a sympathetic nerve system
overactivation (Reis et al., 2000; Tavares et al., 2003). As recognized, long-term nitrate dietary
supplementation might interfere with SNS activity. Thus, notwithstanding the promising previous results
concerning the prevention of CsA-induced BP rise (Reis et al., 2003), the hypothetic impact of this
preventive and regressive/curative Is-5-Mn treatment on peripheral SNS activity should imperatively be
evaluated. Norepinephrine, the main neurotransmitter from the sympathetic nerves, and epinephrine,
which functions as a circulating hormone almost entirely derived from the adrenal medulla, are released
to the circulation upon sympathetic stimulation and then taken by peripheral tissues, such as the heart
and aorta. The platelets, usually seen as peripheral models of the monoaminergic neurons (Stahl, 1985),
selectively uptake catecholamines from the plasma and store them for relatively long periods, thus
overcoming possible regional differences, which is the main problem of plasma catecholamines analysis.
Since platelets are not capable of synthesizing the monoamines, their content derives entirely from those
released into the bloodstream by the adrenals or the SNS terminals and can be considered a reliable and
stable long-term index of SNS activity (Chanberlain et al., 1990). Accordingly, the NE and E contents in
plasma and platelets, as the main indicators of circulating levels, as well in adrenals, heart and aorta, the
key relevant peripheral tissues involved in their synthesis and turnover, might be useful markers of the
peripheral SNS activity in CsA-induced hypertension.
In which the peripheral tissues weights and hypertrophy indexes concerns, there were no significant
differences between any of the groups under study, thus excluding these factors as important
F. Reis et al. / Life Sciences 77 (2005) 2514–25282524contributions for the catecholamines contents impairment. The CsA treatment produced minor
differences on circulating NE and E levels when compared with the control group. The most relevant
effect was an increased platelet NE concentration. Concomitantly, no significant effect was obtained in
adrenals NE and E accumulation. However, left ventricle NE and E and aorta NE contents were lower
than those of the control group. Peripheral tissues, such as the cardiac, take E from the plasma, which is
released from the adrenal medulla upon sympathetic stimulation. The effect obtained might have resulted
from decreased E soaked by the cardiac tissue from plasma and/or from increased release. However,
since the adrenals and plasma E contents were found normal in the CsA group if compared with the
control, there should have simultaneously occurred increased E degradation, which could be due to
increased metabolism and/or conjugation. The NE content in peripheral tissues, such as heart and the
aorta, is governed by the rates of NE release and turnover (which are determined by sympathetic
stimulation and by uptake) and by the synthesis rate (which is mainly dependent of tyrosine
hydroxylation). The decreased ventricle and aorta NE content in the CsA-treated rats might have resulted
from an effect on one or more of the above mechanisms. As previously suggested by other authors, CsA
might increase sympathetic discharge (Xue et al., 1987), which could be not compensated by enough
synthesis. Moreover, in a previous study from our group, it was demonstrated that CsA decreases NE
uptake, probably through a tyramine-like effect on membrane catecholamine transporter (Tavares et al.,
2003). Those findings together support the idea of a combined effect of CsA, both exacerbating NE
release and attenuating its uptake, but a defect on catecholamine synthesis by peripheral sympathetic
nerves should also be considered. The decreased ventricle and aorta NE content is in accordance with the
increased circulating concentration, which was particularly significant in the platelets.
The effects of simultaneous Is-5-Mn and CsA administration were dependent on the kind of treatment:
preventive or regressive therapy. When the CsA action was already established, the Is-5-Mn treatment
had no regressive impact on the decreased ventricle NE and E and aorta NE contents. Concurrently,
adrenals NE and E levels were increased, as occurred in the group treated solely with the nitrate, and NE
platelet concentration was even higher than in the CsA group. Thus, the changes in plasma and
peripheral tissues catecholamine levels induced by previous CsA treatment were not reverted by
subsequent Is-5-Mn administration, which suggests inefficacy of the organic nitrate in this kind of
treatment. On the contrary, when administered before the concomitant treatment with CsA, Is-5-Mn was
able to prevent the CsA-evoked diminishment of left ventricle NE and E and aorta NE contents.
Furthermore, adrenals contents, which were normal in the CsA group, were unaffected. However, there
was a noticeable platelet NE and E reduction compared with the CsA group, indicating that Is-5-Mn
affects platelet catecholamines turnover: uptake, storage, metabolism/conjugation and or release. This
singular effect on platelets, which was also patent in the group treated exclusively with Is-5-Mn, should
be further investigated. Platelet NE and E content decrease was accompanied by an increased plasma NE
concentration and by an augmented aorta E content. Although suggestive, a direct connection between
these changes and the former platelet catecholamine alterations cannot be here addressed.
Interestingly, while the results observed in the group used as regressive therapy (CsA+Is-5-Mn) have
mimic those observed in the CsA group, demonstrating no reversion capacity, the data obtained in the
group used as preventive therapy (Is-5-Mn+CsA) have mimic, in almost all the parameters, those seem
in the group under single Is-5-Mn administration. This finding indicates that Is-5-Mn treatment
determines the catecholamine content variations when used previously (even in those parameters
significantly influenced by the single CsA administration). If the lack of a regressive influence, in
contrast with the beneficial preventive one, is a nitrate tolerance signal cannot be excluded.
F. Reis et al. / Life Sciences 77 (2005) 2514–2528 2525We have previously reported that CsA administration is associated with a decrease of NO-cGMP
contents (Santiago et al., 2003), that might be corrected by previous Is-5-Mn treatment (Reis et al.,
2003). From the present data, it is reliable to consider that the CsA influence on left ventricle NE and E
and aorta NE contents might have a NO deficiency dependency. Studies from other groups have
previously indicated that both the catecholamine release by some blood vessels and by the rat heart
sympathetic nerves might be inhibited by NO (Cohen and Weisbrod, 1988; Schwarz et al., 1995). Thus,
in view of the CsA-induced NO diminishment previously reported in our model (Santiago et al., 2003),
the CsA effects on left ventricle and aorta catecholamines contents might hypothetically be explained by
a suppression of the NO-mediated inhibition of catecholamines release by those tissues. The effect was
prevented when the NO donor was administered as preventive therapy, but was not corrected or
attenuated when the CsA-evoked changes are already established (CsA+Is-5-Mn).
The hypothesis of CsA treatment prolongation as the merely cause for the aggravation/deterioration in
the CsA+Is-5-Mn group (at week 12), in comparison with the 7 weeks of single CsA administration,
cannot be fully denied at this moment. However, our preliminary studies, concerning the definition and
characterization of this animal model of CsA-induced hypertension, have demonstrated that the blood
pressure values and the vascular lesion and platelet morphology profiles were already perfectly
established after 7 weeks of CsA treatment, and that no relevant aggravation is observed by prolonging
the treatment until the week 12. Thus, the cardiovascular worsening effects here reported should be
attributed to additional deleterious actions promoted by the Is-5-Mn per se when the CsA changes are
already established and cannot be reverted or attenuated. In any case, our deep conviction about this
issue should be further confirmed by means of other studies, namely by testing the parameters now
evaluated in a CsA group of 12 weeks.
The precise explanations for the distinct behaviors of Is-5-Mn when used as preventive or as
regressive therapy cannot be addresses taken in consideration only the data now obtained, deserving
further research. However, based on already known information, we would like to raise another key
possibility. As mentioned above, according to previous results from us and from other authors, CsA
promotes a decrease NO availability. Additionally, other studies have been suggesting that CsA
toxicity is at least in part associated with an oxidative stress state (Assis et al., 1997; Pe´rez de Lema et
al., 1998; Kanji et al., 1999) and with changes on reactive oxygen and nitrogen species formation,
which is so far a controversial and under discussion issue (Diederich et al., 1994; Buetler et al., 2000).
The hypothetic CsA-induced formation, in our animal model, of NO-derived oxygen and/or nitrogen
reactive species, such as the superoxide and peroxynitrite, would hypothetically explain some of the
above CsA and Is-5-Mn effects. Actually, peroxynitrite formation is associated with several deleterious
effects, namely in the vasculature (Muijsers et al., 1997) and, according to some authors, also causes
oxidation and nitration of catecholamines, thus decreasing their concentrations (Daveu et al., 1997;
Shelkovnikov et al., 2004). If demonstrated in the ventricle and aorta tissues, the increased NO-
derived peroxynitrite formation would explain the CsA effect on left ventricle and aorta catecholamine
contents as well as the CsA-induced toxicity. Furthermore, it would also explain the prevention of
CsA-induced hypertension by the Is-5-Mn preventively used: the NO donor, by supplying a NO basis,
might prevent the following CsA-induced NO decrease and peroxynitrite formation, thus contributing
to prevent the abovementioned catecholamine changes, as well as the vascular toxicity and
hypertension. On the contrary, when the CsA effects were already established by prior treatment
(CsA+Is-5-Mn group), Is-5-Mn administration was not only unable to revert them but was probably
also responsible for the increased peroxynitrite formation, thus contributing to the even more
F. Reis et al. / Life Sciences 77 (2005) 2514–25282526deleterious effects than those of the single CsA treatment. This interesting hypothesis here raised
deserve, in any case, further research and elucidation, namely by testing if lower nitrate doses also
produced the same dual effects when tested as preventive and regressive/curative therapy for CsA-
induced hypertension.Conclusion
When used as regressive (curative) therapy, Is-5-Mn was unable to revert or attenuate the CsA-
induced plasma, platelets, left ventricle and aorta catecholamine changes and, additionally, the blood
pressure values even worsened. On the contrary, preventive Is-5-Mn treatment prevented the left
ventricle and aorta catecholamine changes, but increased plasma NE and aorta E accumulation. Even
though with those effects, CsA-induced arterial hypertension development was totally prevented. These
findings suggest that the SNS, even of relevance, cannot per se fully explain the CsA-induced arterial
hypertension development, indicating a probable key influence of the NO-cGMP disturbances.
Furthermore, the study also emphasizes that Is-5-Mn might produce beneficial effects only if
preventively used. However, considering the changes on catecholamine contents here reported, a
judicious evaluation of the nitrate therapy impact at a given moment and situation is recommended in
order to avoid further deleterious side effects.Acknowledgments
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